Department of Respiratory Medicine, Radboud University Medical Centre, Nijmegen, Netherlands.
Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, Netherlands.
Tumour Biol. 2024;46(s1):S207-S217. doi: 10.3233/TUB-220034.
The optimal positioning and usage of serum tumor markers (STMs) in advanced non-small cell lung cancer (NSCLC) care is still unclear. This review aimed to provide an overview of the potential use and value of STMs in routine advanced NSCLC care for the prediction of prognosis and treatment response. Radiological imaging and clinical symptoms have shown not to capture a patient's entire disease status in daily clinical practice. Since STM measurements allow for a rapid, minimally invasive, and safe evaluation of the patient's tumor status in real time, STMs can be used as companion decision-making support tools before start and during treatment. To overcome the limited sensitivity and specificity associated with the use of STMs, tests should only be applied in specific subgroups of patients and different test characteristics should be defined per clinical context in order to answer different clinical questions. The same approach can similarly be relevant when developing clinical applications for other (circulating) biomarkers. Future research should focus on the approaches described in this review to achieve STM test implementation in advanced NSCLC care.
血清肿瘤标志物（STM）在晚期非小细胞肺癌（NSCLC）治疗中的最佳定位和使用仍不清楚。本综述旨在概述 STM 在晚期 NSCLC 常规治疗中的潜在用途和价值，以预测预后和治疗反应。影像学和临床症状并不能在日常临床实践中全面反映患者的疾病状态。由于 STM 测量可实时快速、微创且安全地评估患者的肿瘤状态，因此 STM 可作为起始前和治疗期间的辅助决策支持工具。为了克服 STM 使用中固有的敏感性和特异性有限的问题，应仅在特定的患者亚组中应用检测，并根据不同的临床情况定义不同的检测特性，以回答不同的临床问题。在开发其他（循环）生物标志物的临床应用时，同样可以采用这种方法。未来的研究应集中在本综述中描述的方法上，以实现 STM 检测在晚期 NSCLC 治疗中的应用。
